CC-10004

DRUG6 trials

Sponsors

Amgen, Kenneth Peters, MD, NYU Langone Health, University Hospitals Cleveland Medical Center

Conditions

Bechet's DiseaseChronic Prostatitis With Chronic Pelvic Pain SyndromeDiscoid Lupus ErythematosusProstatitisPrurigo NodularisPsoriasisVulvodynia

Phase 1

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

CompletedNCT00708916

NYU Langone HealthDiscoid Lupus Erythematosus

Start: 2008-06-30End: 2010-08-31Updated: 2021-03-03

Phase 2

Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis

CompletedNCT00606450

Start: 2006-04-01End: 2007-05-01Updated: 2020-04-24

An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

CompletedNCT00701311

Kenneth Peters, MDChronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatitis

Start: 2008-06-30End: 2011-03-31Updated: 2014-10-06

CC-10004 For The Treatment Of Vulvodynia

CompletedNCT00814632

Kenneth Peters, MDVulvodynia

Start: 2008-12-31End: 2011-02-28Updated: 2015-08-13

Safety and Efficacy of CC-10004 for Prurigo Nodularis

CompletedNCT00869089

University Hospitals Cleveland Medical CenterPrurigo Nodularis

Start: 2008-09-30End: 2011-01-31Updated: 2016-11-02

Unknown Phase

Expanded Access for CC-10004

AmgenBechet's Disease

Updated: 2020-04-29